| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 12.31 | 62.0% |
| Total Income | 12.31 | 62.0% |
| Expenditure | 48.46 | 8.6% |
| PBT | -36.94 | 22.1% |
| Net Profit | -38.33 | 32.2% |
| OPM | — | |
| NPM | — | |
| EPS | -0.28 | 42.9% |
Coherus Oncology Reports Q1 2026 Financial Results; LOQTORZI Revenue $11.8M
12 May 2026 · 12 May, 1:52 am
Summary
Coherus Oncology reported financial results for the first quarter of 2026. LOQTORZI net revenue was $11.8 million. Net revenue from continuing operations reached $12.3 million. The company's cash, cash equivalents, and marketable securities totaled $167.0 million. Patient accrual is complete for the 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, with data readouts tracking to projections.
Key Highlights
- 1
Coherus Oncology reported LOQTORZI® net revenue of $11.8 million in Q1 2026.
- 2
The company's cash, cash equivalents, and marketable securities totaled $167.0 million at the end of Q1 2026.
- 3
Net revenue from continuing operations was $12.3 million for the three months ended March 31, 2026.
- 4
Patient accrual is complete for the 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, with data readouts tracking to projections.
- 5
The company sold 32,890,000 shares of its common stock in a public offering, generating net proceeds of $53.6 million in Q1 2026.
Management Comments
Denny Lanfear
“We are executing well on our integrated financial, commercial and development strategy that maximizes LOQTORZI’s potential in NPC and in combination with our pipeline products.” “We also continue to explore opportunities across cancers and non-proprietary novel combinations with tagmokitug, our potentially best-in-class CCR8 Treg depleter, and are encouraged given our previously reported clinical data including anti-tumor activity, safety data, tumor biomarker data and PK data.”
Rosh Dias
“Casdozokitug is the only known clinical stage IL-27 antagonist, and the first line HCC study in combination with LOQTORZI is now fully enrolled. We are tracking to initial data around mid-year.” “The tagmokitug program is also on track, with continued enrollment across all cohorts. We also continue to progress the first-in-class pasritamig combination study in metastatic castration-resistant prostate cancer (mCRPC), which we anticipate initiating in the fall. We are on target for multiple data readouts as planned in 2026.”
Informational and educational content only. Not investment advice.